Severe Uncontrolled Asthma clinical trials

Explore recruiting severe uncontrolled asthma clinical trials.

Recruiting severe uncontrolled asthma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Severe Uncontrolled Asthma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma

Poland, Croatia, Bulgaria, Hungary, Germany, Netherlands +4 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma

Latvia, Hungary, Bulgaria, Romania, Portugal, Netherlands +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma

Italy, Slovakia, Spain, Ireland, Belgium, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to assess the efficacy, safety, and tolerability of subcutaneous amlitelimab in adult participants with moderate-to-severe asthma. DRI17509

Italy, Hungary, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2a Randomised, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate to Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA

Sweden, Bulgaria, France, Germany, Denmark, Spain +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicentre, Randomised, Double-Blind, Parallel-Group Placebo-Controlled, Phase 3, Efficacy and Safety Study of Tezepelumab in 5 to < 12 Year Old Children with Severe Uncontrolled Asthma (HORIZON)

Spain, Poland, Hungary, France, Netherlands, Italy +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Severe Uncontrolled Asthma trials by city

Severe Uncontrolled Asthma in Toronto Severe Uncontrolled Asthma in Vancouver Severe Uncontrolled Asthma in Montreal Severe Uncontrolled Asthma in Calgary Severe Uncontrolled Asthma in Edmonton Severe Uncontrolled Asthma in Ottawa Severe Uncontrolled Asthma in Winnipeg Severe Uncontrolled Asthma in Quebec City Severe Uncontrolled Asthma in Hamilton Severe Uncontrolled Asthma in Kitchener Severe Uncontrolled Asthma in London Severe Uncontrolled Asthma in Halifax Severe Uncontrolled Asthma in New York Severe Uncontrolled Asthma in Los Angeles Severe Uncontrolled Asthma in Chicago Severe Uncontrolled Asthma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease